Valuation: ProPhase Labs, Inc.

Market Cap 191K 167K 157K 143K 268K 18.3M 268K 1.88M 724K 9.32M 717K 702K 30.08M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 8.72M 7.6M 7.16M 6.52M 12.23M 835M 12.24M 85.75M 33.05M 426M 32.75M 32.03M 1.37B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
92.7%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-13.79%
1 week+639.64%
Current month+492.42%
1 month+360.95%
3 months+66.67%
6 months+43.51%
Current year-72.07%
1 week 0.01
Extreme 0.01225
0.14
1 month 0.01
Extreme 0.01225
0.14
Current year 0.01
Extreme 0.01225
0.47
1 year 0.01
Extreme 0.01225
6.66
3 years 0.01
Extreme 0.01225
74.8
5 years 0.01
Extreme 0.01225
152.5
10 years 0.01
Extreme 0.01225
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/25 Free

Chief Executive Officer

500,000 1.2036%
17/2/25 Free

Chief Operating Officer

500,000 1.6737%
14/2/25 Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-13.79%+639.64%-96.78%-99.71% 191K
-0.05%+8.20%+106.38%+682.03% 53.25B
+0.22%+1.93%+15.23%+56.66% 26.01B
+1.20%+2.47%-13.20%-35.23% 6.76B
-4.30%-2.55%-2.74%+169.47% 5.98B
+1.24%+0.60%+10.57%+59.01% 3.3B
-3.23%+8.75%-24.81%+2,573.70% 3.02B
-2.56%+5.21%+130.60%+58.77% 2.56B
+18.36%+3.22%+38.58%+47.96% 2.25B
+2.68%+11.00%-6.29%-54.07% 1.91B
Average +0.04%+5.85%+15.76%+345.86% 10.5B
Weighted average by Cap. +0.23%+8.12%+60.21%+444.39%

Financials

2024 2025
Net sales 6.77M 5.9M 5.56M 5.06M 9.49M 649M 9.5M 66.58M 25.66M 330M 25.43M 24.87M 1.07B 4.34M 3.79M 3.57M 3.25M 6.09M 416M 6.1M 42.73M 16.47M 212M 16.32M 15.96M 684M
Net income -53.36M -46.53M -43.82M -39.91M -74.82M -5.11B -74.92M -525M -202M -2.6B -200M -196M -8.4B -14.74M -12.85M -12.11M -11.03M -20.67M -1.41B -20.7M -145M -55.88M -719M -55.38M -54.15M -2.32B
Net Debt 23.9M 20.83M 19.62M 17.87M 33.5M 2.29B 33.55M 235M 90.57M 1.17B 89.76M 87.77M 3.76B 8.53M 7.44M 7M 6.38M 11.96M 817M 11.97M 83.87M 32.33M 416M 32.03M 31.32M 1.34B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
18/09/26 US$0.0123 -17.09% 105,016
17/09/26 US$0.0148 +4.94% 49,274
16/09/26 US$0.0141 -6.13% 46,333
15/09/26 US$0.0150 -1.96% 1,278

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!